SCHEMBL20249368

SCHEMBL20249368

CC(C(=O)O)N1CCN(c2ccc(C(C)(C)C)nc2)C(=O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.37
ROCK2 O75116 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TRPV4 Q9HBA0 1/20 0.32
POLB P06746 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
KDM4E B2RXH2 1/20 0.31
IDH1 O75874 1/20 0.31
LMNA P02545 3/20 0.31
GALR3 O60755 1/20 0.31
TSHR P16473 1/20 0.31
HTT P42858 1/20 0.31
GAA P10253 1/20 0.31
CCR9 P51686 1/20 0.31
MEN1 O00255 1/20 0.31
MAPK1 P28482 1/20 0.31
KMT2A Q03164 1/20 0.31
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249308 0.89 HRH3 (0.38) HRH3TRPV4CYP2D6KDM4EIDH1
SCHEMBL20249310 0.84 HRH3 (0.33) HRH3ROCK2L3MBTL1KDM4EIDH1
SCHEMBL20255222 0.83 HRH3 (0.38) HRH3ROCK2POLBCYP1A2CYP2D6
SCHEMBL20249390 0.81 IDH1 (0.33) HRH3IDH1
SCHEMBL20249339 0.81 HRH3 (0.43) HRH3TRPV4CYP2D6KDM4ELMNA
SCHEMBL20249115 0.77 SLC6A2 (0.42) HRH3L3MBTL1LMNAGALR3TSHR
SCHEMBL20249342 0.77 PARP1 (0.35) HRH3
SCHEMBL20249300 0.76 PIK3CD (0.43) HRH3L3MBTL1IDH1MAPK1
SCHEMBL20249475 0.76 HRH3 (0.36) HRH3CYP1A2CYP2D6CYP2C9KDM4E
SCHEMBL20249478 0.76 HRH3 (0.36) HRH3CYP1A2CYP2D6CYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 HRH3 2304/4885ROCK2 3168/4885L3MBTL1 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.